4.6 Article

Synbiotics Alleviate the Gut Indole Load and Dysbiosis in Chronic Kidney Disease

Journal

CELLS
Volume 10, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/cells10010114

Keywords

synbiotics; gut indole; dysbiosis; chronic kidney disease

Categories

Funding

  1. Yin Yen-Liang Foundation Development and Construction Plan of the School of Medicine, National Yang-Ming University, Taipei, Taiwan [107F-M01-0504]
  2. Ministry of Science and Technology (MOST), Taiwan [MOST 105-2628-B-075-008-MY3, MOST 108-2633-B-009-001, MOST 109-2314-B-010-053-MY3, MOST 109-2321-B-009-007]
  3. Taipei Veterans General Hospital, Taipei, Taiwan [V106D25003-MY3, VGHUST107-G5-3-3, VGHUST109-V5-1-2]
  4. Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B) from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan

Ask authors/readers for more resources

CKD patients show alterations in gut microbiota diversity, which can be treated with synbiotic therapy to reduce harmful bacteria and restore levels similar to healthy controls. ESKD patients have similar levels of indole-producing bacteria compared to healthy controls, but significantly higher blood levels of indoxyl sulfate.
Chronic kidney disease (CKD) has long been known to cause significant digestive tract pathology. Of note, indoxyl sulfate is a gut microbe-derived uremic toxin that accumulates in CKD patients. Nevertheless, the relationship between gut microbiota, fecal indole content, and blood indoxyl sulfate level remains unknown. In our study, we established an adenine-induced CKD rat model, which recapitulates human CKD-related gut dysbiosis. Synbiotic treatment in CKD rats showed a significant reduction in both the indole-producing bacterium Clostridium and fecal indole amount. Furthermore, gut microbiota diversity was reduced in CKD rats but was restored after synbiotic treatment. Intriguingly, in our end-stage kidney disease (ESKD) patients, the abundance of indole-producing bacteria, Bacteroides, Prevotella, and Clostridium, is similar to that of healthy controls. Consistently, the fecal indole tends to be higher in the ESKD patients, but the difference did not achieve statistical significance. However, the blood level of indoxyl sulfate was significantly higher than that of healthy controls, implicating that under an equivalent indole production rate, the impaired renal excretion contributes to the accumulation of this notorious uremic toxin. On the other hand, we did identify two short-chain fatty acid-producing bacteria, Faecalibacterium and Roseburia, were reduced in ESKD patients as compared to the healthy controls. This may contribute to gut dysbiosis. We also identified that three genera Fusobacterium, Shewanella, and Erwinia, in the ESKD patients but not in the healthy controls. Building up gut symbiosis to treat CKD is a novel concept, but once proved effective, it will provide an additional treatment strategy for CKD patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available